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The Year in Review of
Clinical Cardiac Electrophysiology
Gregory M. Marcus, MD, MAS,* Edmund Keung, MD,y Melvin M. Scheinman, MD*
San Francisco, CaliforniaThis review encompasses articles that were published
between April 1, 2012, and May 21, 2013, in the ﬁeld of
cardiac electrophysiology that were felt to be particularly
relevant to general cardiologists. The year saw many
contributions that are pertinent to both researchers and
clinicians. Due to space constraints, we apologize for the
required omission of many excellent studies.
Clinical Electrophysiology
Atrial ﬁbrillation. With the growing recognition that
asymptomatic atrial ﬁbrillation (AF) is an important risk
factor for stroke, the natural question arises: how to best
identify individuals with undetected, or subclinical, AF
that would beneﬁt from anticoagulation therapy? Swedish
investigators administered a stepwise screening program of
848 75- to 76-year-olds from a single municipality (Fig. 1)
(1). Only 35 (43%) of the 81 with a previous AF diagnosis
were already on anticoagulation therapy (17, 35%, of those
35, started anticoagulation after the screening). A 12-lead
electrocardiogram (ECG) at a single time point then iden-
tiﬁed 10 more patients (1.2%) with AF; these participants
had a mean CHADS2 (congestive heart failure, hyperten-
sion, age 75 years, diabetes mellitus, prior stroke or tran-
sient ischemia attack, or thromboembolism) score of 1.8.
Participants without evidence of AF and a CHADS2 score
of 2 (n ¼ 403 after 16 declined) were then provided
a handheld device capable of recording a single-lead ECG
with instructions to use the device for 20 to 30 s twice daily
for 2 weeks. The 48-h Holter studies were employed in 10
cases that were difﬁcult to interpret, most often with
a suspicion of AF. Thirty (7.4%) of the 403 received a new
diagnosis of AF. The mean CHADS2 score of those 30 was
2.5, and 6 had a previous stroke. Therefore, the total prev-
alence in the screened population was 14.3%, and 5.2% were
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strates that a substantial proportion of previously undiag-
nosed AF can be detected by simple screening procedures.
Ultimately, such ﬁndings could translate into a large reduc-
tion in stroke. While new technologies will likely make
such strategies more feasible in the future, other efforts to
identify populations at the highest risk will also be important
in order to optimize resources and cost-effectiveness. As
we consider utilizing new sophisticated technologies with
continuous monitoring capabilities, it is also important to
emphasize that the relationship between AF duration and
stroke remains poorly deﬁneddindeed, the exact “cutoff”
duration of clinical relevance has not yet been determined,
and, as suggested by previous work showing a temporal
dissociation between AF episodes and strokes (2), the
pathophysiologic mechanisms underlying the AF-stroke
relationship require further elucidation.
In the spirit of identifying AF patients at highest risk of
stroke, a paper by Tsadok et al. (3) sought to hone in on
female sex as a predictor of stroke. While women have been
shown to be at a higher risk for stroke in the setting of AF,
some have postulated that this may be related to reduced use
of appropriate anticoagulation among women. The distinc-
tion is clearly clinically relevant and can result in confusion
for treating physicians. For example, while the CHADS2
score (1 point each for congestive heart failure [HF],
hypertension, age 75 years, diabetes, and 2 points for
a history of stroke or transient ischemic attack) (4) does not
consider the sex of the patient, the CHA2DS2-VASc score
(5,6), a system developed as a compliment to CHADS2
primarily in risk-stratifying the lower CHADS2 patients,
does (including a similar scoring scheme as CHADS2 with
the exception of 1 point for ages 65 to 75 years, 2 points for
age 75 years, 1 point for vascular disease, and 1 point for
female sex). Avgil Tsadok et al. analyzed an administrative
dataset of 39,398 women and 44,115 men discharged from
the hospital with a primary diagnosis of AF in Quebec (3).
The overall incidence of stroke was 2.02 (95% conﬁdence
interval: 1.95 to 2.10) per 100 person-years in women versus
1.61 (95% CI: 1.54 to 1.69) per 100 person years in men.
The higher risk among women was consistent across
CHADS2 scores, but greater among those with CHADS2
score of 2 or 3. The enhanced risk was also particularly
strong among elderly women (75 years). These differences
Figure 1 Study Flow With Regard to ECG Diagnostics in a Stepwise Screening of AF
AF ¼ atrial ﬁbrillation; CHADS2 ¼ congestive heart failure, hypertension, age >75 years, diabetes, stroke (doubled); ECG ¼ electrocardiography. Reprinted with permission from
Engdahl et al. (1).
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2434were not explained by warfarin use. After adjustment for
comorbidities, CHADS2 score, and warfarin use, women
exhibited a 14% greater risk (hazard ratio [HR]: 1.14, 95%
CI: 1.07 to 1.22) of stroke compared to men. Importantly,
there were no signiﬁcant differences in intracerebral
hemorrhages or hemorrhage in general by sex. Despite the
limitations inherent to a study utilizing administrative data,
these ﬁndings in combination with similar studies in the past
provide strong evidence that women are at a higher risk of
stroke in the setting of AF. The mechanism remains unclear,
and these ﬁndings suggest that women may require more
aggressive anticoagulation even when it is appropriately
prescribed. These data also point to the utility of the
CHA2DS2-VASc score when counseling AF patients
regarding their risk and when seeking to identify those AF
patients most likely to beneﬁt from anticoagulation therapy.
Future studies may help to reﬁne this risk further, poten-
tially via genetic or biomarker studies. For example, this year
included the ﬁrst demonstration that biomarkers may be
useful in this regard: a secondary analysis of the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation
Therapy) trial demonstrated that baseline levels of troponin I
and N-terminal pro–B-type natriuretic peptide may addadditional prognostic information regarding thromboembo-
lism in AF patients to these traditional scoring systems (7).
In addition, recent evidence suggests that renal dysfunction,
a readily clinically evident comorbidity, is an important
risk factor for stroke in AF even independent of CHADS2
and CHA2DS2-VASc scores (8–10).
As the novel anticoagulants are incorporated into clinical
practice, questions regarding speciﬁc applications are
becoming more common. Cardioversion and catheter abla-
tion of AF are 2 circumstances where risk of thromboem-
bolism is particularly high: the overall incidence of stroke is
estimated to be 1.5% in cardioversion patients not receiving
anticoagulation (11), and the incidence of clinically evident
thromboembolism following AF ablation is reported to
be between 0% and 7% (12). A post-hoc analysis of the
ROCKET AF (Rivaroxaban Once-daily, oral, direct Factor
Xa inhibition Compared with vitamin K antagonism for
prevention of stroke and Embolism Trial in Atrial Fibril-
lation) trial found that use of rivaroxaban surrounding these
procedures appears to be safe and at least similar to the use of
warfarin (13). Consistent with previous reports, the rate of
stroke or death in the ﬁrst 30 days after electrical car-
dioversion, pharmacologic cardioversion, or catheter ablation
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2435for AF was increased (a rate of 0.93% for stroke and 1.25%
for death). Importantly, in this secondary analysis, it is
difﬁcult to know if some of this was due to “effect cause”
(i.e., those who were sicker and therefore more likely to die
were more likely to have cardioversion performed). Indeed,
patients with plans for elective cardioversion or restoration of
sinus rhythm during screening were excluded from enroll-
ment in the trial; following study entry, patients who
required cardioversion due to hemodynamic instability,
progressive HF, or refractory symptoms despite optimal
medical therapy could undergo cardioversion or AF ablation
per study protocol. The important message from this study
was that these rates were not meaningfully different bet-
ween those on rivaroxaban versus those on warfarin. Two
important limitations of this study should be considered: no
data on transesophageal echocardiograms were available and
data regarding speciﬁc periprocedure international normal-
ized ratio (INR) values were not included.
Despite our growing options for anticoagulation in AF,
warfarin remains the mainstay in stroke and thrombo-
embolism prevention. Recognizing that risk prediction is
primarily relevant in considering the relative risk of bleeding,
new research this past year helped to better conceptualize
this important balance. The net clinical beneﬁt (considering
stroke/thromboembolism and bleeding) of warfarin was
calculated for 182,678 Swedish AF patients identiﬁed
through the Swedish National Hospital Discharge Register
(14). CHADS2 and CHA2DS2-VASc scores were consid-
ered for thromboembolic risk, and a modiﬁed version of
the HAS-BLED score (which considers hypertension,
abnormal renal/liver function, stroke, bleeding history or
disposition, labile INR [ignored for this study], elderly,
drugs/alcohol) derived from this administrative dataset to
the best of the investigators’ ability was used as the bleeding
risk score. The net beneﬁt was calculated as the risk of
ischemic stroke off warfarin minus the risk of intracranial
hemorrhage on warfarin. A secondary analysis that gave
more weight to intracranial hemorrhage using a calculation
previously described by Singer et al. was also analyzed (15).
Regardless of whether the CHA2DS2-VASc or the HAS-
BLED score was used, the risk of ischemic stroke
increased more than the risk of bleeding as the risk score
increased. The net beneﬁt favored warfarin for all CHADS2
score patients and all CHA2DS2-VASc scores except 0.
Those with the best net beneﬁt from warfarin had the
highest risk scores for both stroke and bleeding. Indeed,
when the risk of bleeding is high per the HAS-BLED score,
the risk of ischemic stroke is even higher. The authors
suggest that a simple approach would be to regard anti-
coagulation as the general rule for AF patients, with
the exception of the very low risk patient (CHA2DS2-
VASc ¼ 0) or the patient at very high risk of bleeding.
Important limitations to this study include the fact that it
was observational (therefore, confounding “by indication”
may have played a role in this nonrandomized study), the
data was derived from an administrative dataset (thereforecoding issues could have affected accuracy), and bleeding
events other than intracranial bleeding, including fatal or
life-threatening bleeding, were not taken into account.
Moving from medications to devices for stroke preven-
tion, 2 important follow-up studies to the PROTECT AF
(Watchman Left Atrial Appendage System for Embolic
Protection in Patients with Atrial Fibrillation) trial were
published this past year. Brieﬂy and as described in detail in
our previous review (16), the PROTECT AF trial involved
the randomization of 707 AF patients with at least 1 stroke
risk factor to the Watchman device (a percutaneously placed
left atrial appendage occlusion device) versus warfarin in
a 2:1 fashion (17). The device was found to be noninferior to
warfarin for the combined endpoint of stroke, systemic
embolism, and cardiovascular death. Importantly, those
receiving the device were treated with warfarin forw45 days
followed by clopidogrel for 4.5 months and then lifelong
aspirin. Because only 30% of patients had been followed for
>2 years in the original publication, the success of the device
could have been attributed in part to the ongoing anti-
coagulation that was received. Therefore, a second manu-
script with longer follow-up, mean 2.3  1.1 years (range
0 to 5.9 years), was published this year (18). All patients in
the control group received warfarin therapy (time in thera-
peutic INR range was 66%); 34% of control patients inter-
rupted anticoagulation at some point due to invasive
procedures (58%), hemorrhage (17%), elevated INR values
(9%), or other reasons (18%). Among 463 patients assigned
to the closure device, successful implantation was achieved in
408 (88%); during follow-up, 86.8%, 92.2%, and 93.2%
stopped taking warfarin at 45 days, 6 months, and 1 year,
respectively. The composite primary endpoint of stroke,
systemic embolism, and cardiovascular death was 3.0% per
year in the Watchman group and 4.3% in the control
(warfarin) group (relative risk [RR]: 0.71, 95% CI: 0.44 to
1.30). Although no statistically signiﬁcant differences were
detected in individual comparisons, the device group
exhibited more ischemic strokes, but less cardiovascular
death and less hemorrhagic stroke. The primary safety end
point, which included both procedure-related events
(including pericardial effusion requiring intervention or
hospitalization, procedure-related stroke, or device embo-
lization) and major bleeding (intracranial bleeding or
gastrointestinal bleeding requiring transfusion) was higher in
the device group (5.5% per year) than the control group
(3.6% per year) for a RR of 1.53 (95% CI: 0.95 to 2.70). Of
note, patients with a previous history of stroke or transient
ischemic attack appeared to receive sustained beneﬁt from
the device that was at least as good as warfarin therapy.
In summary, it appears that the noninferiority of this left
atrial appendage occlusion device compared to warfarin was
sufﬁciently maintained at longer follow-up. Because the
device group experienced more “up-front” adverse events
(regarding both safety events as well as some ischemic stroke
outcomes) while the bleeding risks of warfarin will likely
accumulate over time, the relative beneﬁt of the device may
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these data involved the report of differential effects on
quality of life in the same trial: using serial Short-Form 12
Health Surveys at baseline and 12 months, those random-
ized to the closure device exhibited more favorable changes
in quality of life scores compared to those randomized to
warfarin (19). The improvements were primarily in physical
functioning and did not seem to differ amongst the warfarin
naïve and those previously treated with warfarin.
Several interesting studies on ablation of AF were re-
ported this year, ranging from a more in-depth exploration
of current practices to the promise of new technologies. The
majority of previous trials comparing AF ablation to anti-
arrhythmic drugs have enrolled patients that have previously
failed an antiarrhythmic drugdtherefore, a common criti-
cism is that the control group may be “destined to fail.”
Cosedis Nielsen et al. published the ﬁrst major trial to
compare AF ablation to ﬁrst-time antiarrhythmic drugs in
antiarrhythmic drug-naïve AF patients: the MANTRA-
PAF (Medical Antiarrhythmic Treatment or Radio-
frequency Ablation in Paroxysmal Atrial Fibrillation) trial
randomized 294 symptomatic paroxysmal AF patients 70
years of age to conventional pulmonary vein isolation (PVI)
via percutaneous transvenous radiofrequency catheter abla-
tion versus treatment with a Class IC or III antiarrhythmic
drug (20). Clinical follow-up and 7-day Holter monitor
recordings were scheduled at 3, 6, 12, 18, and 24 months. In
the ablation group, 140 patients (96% of those assigned to
the ablation arm) underwent a mean 1.6  0.7 procedures.
At 24 months (the end of the study period), 13 patients in
the ablation group were receiving antiarrhythmic drugs.
In the medication group, 146 patients (99% of patients
assigned to drugs) were treated with either a Class 1C drug
(n ¼ 131) or a Class III drug (n ¼ 15). The mean number of
agents used during the study was 1.26  0.46. Fifty-four
patients (36%) in the drug group underwent an AF abla-
tion procedure. Although AF burden was reduced signiﬁ-
cantly from baseline in both groups, no differences in the
primary endpoints of burden of AF (deﬁned as the
percentage of time in AF on each Holter recording) or
cumulative burden (a sum across all Holters) was observed.
However, those in the AF ablation group exhibited a lower
burden of AF at 24 months (90th percentiles of 9% vs. 18%
in the drug group, p ¼ 0.007), were more often free of any
AF (85% vs. 71% in the drug group, p ¼ 0.004), and more
often free of symptomatic AF (93% vs. 84%, p ¼ 0.01) at 24
months. Quality of life scores also improved signiﬁcantly in
both groups over time, with evidence that the physical
activity score improved more over time in the ablation group
compared to the drug group. The total number of serious
adverse events did not differ between groups. Three ablation
patients had procedure-related tamponade, and 1 patient
died due to a procedure-related stroke. While other causes of
death were similar over follow-up (3 in the ablation arm and
4 in the drug arm), there was a sudden death in each group
and the relationship to antiarrhythmic drug use was notdescribed in detail. This interesting study with aggressive
Holter monitoring demonstrated some evidence of superi-
ority of ablation, but the magnitude of the difference
compared to ﬁrst-time antiarrhythmic drug therapy was
much smaller than in previous studies (where the deck is
more likely stacked against those that have already failed at
least 1 antiarrhythmic drug). The efﬁcacy of antiarrhythmic
drugs was in fact quite high in this study. While the authors
conclude that these data support the general recommenda-
tion to reserve AF ablation for those that have failed at least
1 antiarrhythmic drug, additional future studies are still
needed to better deﬁne differences in cost, healthcare utili-
zation, and long-term cardiovascular outcomes in order to
more fully inform that decision. Important limitations of
this study should be recognized: because the study was
restricted to those with paroxysmal AF, it would be inap-
propriate to extrapolate these ﬁndings to patients with
persistent AF. In addition, because the authors did not
report the doses of the antiarrhythmic drugs prescribed, it
remains possible that some of the drug failures were related
to inadequate dosing. Finally, because this study represented
a younger AF population (restricted to age 70 years and
with an average age of 55  10 years), these data should
not be extrapolated to older age groupsdthis is particularly
important because the majority of AF patients in the United
States would be too old to participate in this study (21,22).
AF is particularly problematic in HF patients, and the
optimal method to treat AF in this setting is yet to be
determined. The AF-CHF (Atrial Fibrillation and Con-
gestive Heart Failure) trial failed to demonstrate a beneﬁt
of a rhythm control strategy using medications over rate
control (23), but there is evidence that HF patients might
beneﬁt from sinus rhythm if it can be maintained (24,25).
In the ARC-HF (A Randomised Trial to Assess Catheter
Ablation Versus Rate Control in the Management of
Persistent Atrial Fibrillation in Chronic Heart Failure)
trial, 52 patients with symptomatic HF, a left ventricular
ejection fraction (LVEF) 35%, and persistent AF were
randomized to catheter ablation or rate control (26). Patients
were followed at 3, 6, and 12 months. At 12 months, the
peak VO2 (the primary endpoint) increased by 2.13 (–0.10
to þ4.26) ml/kg/min in the ablation arm compared to
a mean decrease of 0.94 (–2.21 to þ0.32) ml/kg/min in the
rate control arm (p ¼ 0.018). Several other parameters
trended toward improvement at 3 months and achieved
statistical signiﬁcance at 6 and 12 months with ablation,
including Minnesota Living with Heart Failure Question-
naire scores and reductions in B-type natriuretic peptide
levels. There was a strong trend toward improvement in
LVEF with ablation that did not reach statistical signiﬁ-
cance (p ¼ 0.055). This small study suggests that, counter
to some general perceptions, HF patients may in fact
beneﬁt particularly well from AF ablation. These ﬁndings
ﬁt well with a previous randomized comparison demon-
strating better outcomes with AF ablation versus AV node
ablation and biventricular pacing (27). It is important to
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cally relevant, did not include “hard” outcomes such as HF
hospitalizations or death, and there was no comparison to
a group of HF patients undergoing cardioversion and/or
sinus rhythm maintenance with medications. In addition,
the particular AF ablation procedures employed, while
entirely appropriate, were quite extensive and time con-
suming (including PVI, mitral isthmus and roof line ablation
with demonstration of block, ablation of complex fraction-
ated electrograms, and mapping and ablation of atrial
tachycardias as well as cavotricuspid isthmus ablation as
indicated)dsimilarly rigorous procedures may not be easily
reproduced amongst the more general variety of practicing
electrophysiologists and therefore extrapolation of these
results may be limited to the most experienced centers. The
delayed and then sustained superiority of ablation suggests
a cumulative beneﬁt over time in these patients, demon-
strating the need for adequate follow-up when assessing
these different treatment modalities.
A particularly fascinating manuscript describing AF
recurrences as measured by implantable cardiac monitors
(ICMs) after AF ablation was published this past year (28),
building on the important observation that the proportion of
asymptomatic AF episodes detected by intermittent 7-day
Holter sessions increased after AF ablation (29). In short,
this study conﬁrmed that, while AF ablation really does
work to reduce AF, some of the beneﬁts appear to be related
to an increase in asymptomatic episodes. After following 50
AF ablation patients for 18 months using ICMs, symptom
diaries, and 48-h Holters at 3, 6, 9, and 12 months, the total
atrial arrhythmia burden (including AF, atrial ﬂutter, and
atrial tachycardia) was reduced by 86% from a mean 2.0 
0.5 h per day before to a mean 0.3  0.2 h per day after
ablation (p < 0.001). When recurrence was deﬁned on the
basis of symptoms alone, 58% were arrhythmia free; if based
on symptoms or serial electrocardiograms and Holters, 56%
were arrhythmia free; and if based on ICM, 46% were
arrhythmia freedtherefore, 12% had exclusively asymp-
tomatic episodes that would not have been detected using
conventional methods alone. Also of interest, ablation itself
increased the proportion of asymptomatic episodes: the
proportion of episodes that were asymptomatic increased
from 52% before to 79% after ablation (p ¼ 0.002), and the
ratio of asymptomatic to symptomatic AF episodes increased
from 1.1 before to 3.7 after ablation. Independent predic-
tors of more asymptomatic episodes of atrial arrhythmias
included the post-ablation state (the strongest predictor),
a larger number of atrial ﬂutter or atrial tachycardia episo-
des, lower heart rates, less heart rate variability, and shorter
episode duration. The mechanism underlying the ablation-
asymptomatic episode relationship remains unknown.
While there may be an important placebo effect, the
conversion to more organized arrhythmias (which may result
in a more regular ventricular response) and potentially vagal
denervation (that may result in less heart rate variability)
after ablation may also contribute. Because the primaryrationale for ablation is reduction in symptoms and
improvement in quality of life, these improvements may
be clinically relevant, even if they do not mean a complete
eradication of arrhythmias. The most important lesson
from this report is that we must be wary of assuming a “cure”
of AF, particularly when considering stroke prophylaxis.
Indeed, none of the current AF guidelines recommend
withholding or discontinuing anticoagulation based on
clinical evidence of sinus rhythm maintenance, an especially
relevant practice given that only 6 min of pacemaker-
detected AF may be sufﬁcient to increase the risk of
stroke (30).
One of the more advanced new technologies, now
approved for clinical use by the Food and Drug Adminis-
tration, is the “cryoballoon.” The theoretical advantage is
that a single application of freezing temperatures via a
balloon ﬁt in a pulmonary vein might more quickly and
more easily achieve electrical isolation between a pulmonary
vein and the left atrium than point-by-point ablations with
a conventional catheter delivering radiofrequency energy.
The STOP AF (A Clinical Study of the Arctic Front
Cryoablation Balloon for the Treatment of Paroxysmal
Atrial Fibrillation) trial randomized 245 paroxysmal AF
patients that had previously failed 1 antiarrhythmic drug
in a 2:1 fashion to cryoballoon ablation versus drug therapy
(31). Patients were monitored with visits at 1, 3, 6, 9, and
12 months, transtelephonic transmissions were sent weekly
or for arrhythmia symptoms, and 24-h Holter studies were
obtained at 6 and 12 months. All 4 major pulmonary veins
were isolated in 97.6% of patients, and 4.9% required
catheter-based focal cryoablation. The mean procedure time
was 371 min, with a mean ﬂuoroscopy time of 63 min.
Thirty-one of the 163 assigned to cryoablation required
a repeat procedure in the ﬁrst 90 days (blanking period),
and 65 of the 83 receiving drugs crossed over to receive
cryoablation. At 12 months of follow-up, 70% of the
cryoballoon-ablated patients achieved the primary effec-
tiveness endpoint: free of evidence of AF without any new
drug therapy and in the absence of repeat ablation after
the 90 day blanking period. Of these, 13 (8% of those
initially assigned to cryoablation and 11% of those deemed
a “success”) were on drug therapy that was previously inef-
fective at the same or lower dose than prior to the ablation.
The single procedure success rate was 58%. Only 6 (7%) of
those assigned to antiarrhythmic drugs achieved the primary
effectiveness endpoint. Adverse events in the cryoablation
group included 1 periprocedural myocardial infarction, 1
cardiac tamponade, 2 symptomatic pulmonary vein stenosis
cases where intervention was recommended, 1 patient with
atrial ﬂutter requiring prolonged hospitalization, 2 arterio-
venous ﬁstulas, and 2 pseudoaneurysms. One patient had
a procedure-related stroke. Pulmonary vein stenosis deﬁned
as a >75% reduction in cross sectional area occurred in 3%
and phrenic nerve paralysis occurred in 11% of those that
underwent cryoablation. The great majority (25 of 28) of
those with phrenic nerve injury showed complete recovery
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frequency ablation, cryoballoon ablation appears to have
superior efﬁcacy to antiarrhythmic drugs (in those that have
previously failed an antiarrhythmic drug) but at the cost of
more up-front risks. An important limitation is that some
drugs known to be particularly efﬁcacious in maintaining
sinus rhythm, dofetilide and amiodarone, were not allowed
in this study. One hope was that cryoablation would not
result in 1 of the most lethal complications of AF ablation,
atrioesophageal ﬁstulas; while no such complication was
found in the STOP AF trial, there have now been reports
of esophageal injury (32,33) and an atrioesophageal ﬁstula
(34) using this technology. In order to determine the
durability of the response to cryoballoon ablation, another
analysis published this year described the outcomes of 605
consecutive AF patients that underwent the procedure with
a mean follow-up of 33.4  17.3 months: rates of freedom
from AF without and with repeat procedures were 62%
and 77% (35), again similar to previous reports after radio-
frequency ablation. A direct comparison between cry-
oballoon and radiofrequency ablation technologies is
ongoing as part of the FIRE AND ICE (An Investigator
Initiated, Randomized, Open, Blinded Outcome Assess-
ment, Comparing Efﬁcacy and Safety of Isolation of the
Pulmonary Veins With a Cryoballoon Catheter Versus
a RF Ablation With a ThermoCool Catheter in Patients
With PAF) trial (NCT01490814).
As a potential glimpse into the future for our AF ablation
patients, a small trial randomized 27 AF patients refractory
to antiarrhythmic drugs and with drug-resistant hyperten-
sion (systolic blood pressure >160 mm Hg despite triple
drug therapy) to conventional PVI versus PVI and renal
denervation using the recently describe percutaneous radio-
frequency ablation technique (36). At the end of 1 year of
follow-up, signiﬁcant reductions in systolic and diastolic
blood pressures were observed only in the renal denervation
group. Nine (69%) in the PVI with renal denervation group
versus 4 (29%) in the PVI only group were free of AF (p ¼
0.033). While the reasons for such a poor success rate in the
PVI-only group remain unclear (and may simply reﬂect the
pathophysiology of AF in these poorly controlled hyper-
tensive patients), the different outcomes in this pilot study
were dramatic, providing an intriguing foundation for future
studies.
Ventricular arrhythmias. With the recent recognition that
some patients with an early repolarization (ER) pattern on
their 12-lead ECG may be at high risk of sudden death,
attention has shifted back to the clinical relevance of this
commonly encountered ECG ﬁnding. Walsh et al. exam-
ined the predictors and natural history of ER in 5,069
participants in the CARDIA (Coronary Artery Risk
Development in Young Adults) cohort. “Deﬁnite” ER was
deﬁned on serial ECGs taken at baseline (mean age 25
years), year 7, and year 25 if there was ST-segment
J elevation >1 mm in 50% of beats, T-wave amplitude
5 mm, prominent J point, upward concavity of theST-segment, and a distinct notch or slur on the downstroke
of the R-wave in any of leads V3 to V6. Whereas 941
(18.6%) exhibited an ER pattern at baseline, only 119 of
2,505 participants (4.8%) had it by year 20. Development of
new ER over time was very rare. Younger age, black race,
male sex, longer exercise duration and QRS duration, and
lower body mass index, heart rate, QT index, and Cornell
voltage were associated with the presence of ER. Predictors
of maintenance of ER from baseline to year 20 included
black race, lower body mass index, lower serum triglyceride
levels, and longer QRS duration. No analyses related to
outcomes (e.g., sudden death or mortality) were included.
The authors speculate that the ER pattern they observed,
which was also found to be associated with better exercise
ﬁtness and a lower resting heart rate (perhaps indicative of
more vagal tone) represents a “less ominous” ER phenotype
that may wane over time; in contrast, the more lethal
phenotype may be related to an arrhythmic substrate that
persists over time. Importantly, the deﬁnition of ER was
different from that used in previous reports involving sudden
death risk: as described in our previous reviews (16,37), ST-
segment elevation in V1 to V3 was generally previously
excluded (38,39) and ER (or “J-point elevation” or “slurring”
or “notching”) in the inferior leads was included (40). In
fact, 1 previous study found that the J-point elevation in the
inferior leads was more common in ventricular ﬁbrillation
(VF) patients, whereas young healthy athletes more often
exhibited the pattern in leads V3 to V6 (39). In an
accompanying editorial, Dr. Lombardi builds on a previous
commentary by Viskin et al. (41) to suggest that there might
be a “type A” ER pattern detected in young, asymptomatic
physically active people with a predominant ST-segment
elevation in the precordial leads versus a “type B” pattern
found in middle-aged individuals with a prominent J-wave
and more horizontal ST-segment elevation reﬂective of
increased dispersion of repolarization prone to ventricular
arrhythmias (42).
While catheter ablation for ventricular tachycardia (VT)
is likely an important modality to reduce painful implan-
table cardioverter-deﬁbrillator (ICD) shocks, the mortality
beneﬁt of this procedure remains unclear. Investigators in
Milan, Italy, described their experience forming a dedicated
VT unit focused on the management of patients with VT
and structural heart disease (43). This 24 hours a day, 7 days
a week unit bridges the electrophysiology laboratory with
the emergency department and intensive care unit as well
as HF and cardiothoracic surgery specialists. All high-risk
patients (deﬁned by the severity of their VT and comor-
bidities) underwent catheter ablation and all low-risk
patients underwent electrophysiological evaluation with
ablation employed if indicated. Catheter ablation was per-
formed in 528 of 616 patients with VT episodes attributed
to a scar-related substrate over a 4-year period. Amiodarone
was maintained after discharge in only 32%. Over a
26-month follow-up available in 472 patients, VT recurred
in 34%; predictors of VT recurrence included failed catheter
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with electrophysiological testing at the end of the proce-
dure), presence of nontolerated VT, and post-ablation
amiodarone therapy. Predictors of cardiac mortality in-
cluded higher New York Heart Association (NYHA)
functional class, presence of electrical storm, chronic kidney
disease, and the success of the ablation procedure (higher
cardiac mortality was associated with failure of the proce-
dure). While a comparison group that did not undergo
ablation was not a focus of this paper and while residual
confounding despite efforts to adjust for known confounders
could explain the observation that more successful proce-
dures were associated with better long-term outcomes (e.g.,
perhaps the healthier people were more likely to have
a successful procedure), these data suggest that a successful
catheter ablation of VT as determined by acute VT induc-
ibility immediately after ablation may result in less VT
recurrences (which generally translates into less ICD
shocks), less hospitalizations, and less cardiac death.
The American Heart Association guidelines for cardio-
pulmonary resuscitation and emergency cardiovascular care
were changed in 2005 and reiterated in 2010 to increase the
proportion of time devoted to chest compressions during
resuscitation (manifested by reducing the number of back-
to-back rhythm analyses and shocks, eliminating rhythm
and pulse checks immediately after each shock, increasing
the ratio of chest compressions to ventilation, and doubling
the required period of cardiopulmonary resuscitation [CPR]
between successive rhythm evaluations) (44,45). While
some studies demonstrated an improvement in outcomes
for patients with a VF or VT arrest (46–48), Kudenchuk
et al. provided an analysis this year to examine the effect on
nonshockable rhythms (49). The outcomes during a 5-year
period after adoption of the new resuscitation guidelines
were compared to the previous 5 years among 3,960 patients
with nontraumatic out-of-hospital cardiac arrest (OHCA)
in the absence of a shockable rhythm in King County,
Washington. After adjustment for potential confounders,
the years after adoption of the new guidelines were associ-
ated with an approximate 50% greater odds of return
of spontaneous circulation, hospital survival, a favorable
neurologic status, and 1 month survival. The adjusted odds
of 1-year survival was 85% higher (odds ratio: 1.85, 95% CI:
1.29 to 2.66). Interaction testing revealed that the observed
beneﬁt was driven primarily by those with an arrest with
a cardiac cause, consistent with the notion that the beneﬁt of
a greater proportion of chest compressions has to do with
improving blood ﬂow (rather than ventilation for example).
Although an important limitation of this study is that
general temporal trends cannot be excluded as the primary
explanation for the beneﬁt, there was no clear temporal trend
in these outcomes within the 2 study periods, suggesting
that the change in the guidelines was causal; indeed, in
a subanalysis of a small sample with automatic electronic
deﬁbrillator recordings, the proportion of resuscitation
devoted to chest compressions increased signiﬁcantly in the5 years after the guideline change. Therefore, the beneﬁt of
increasing the proportion of chest compressions during CPR
as per the most recent guidelines appears to beneﬁt those
with and without initial shockable rhythms.
In line with these ﬁndings, an analysis of 2 previous
trials involving randomization of dispatcher CPR instruction
to chest compression alone versus chest compression plus
rescue breathing determined long-term follow-up using
national and state death records (50). Among 2,496 partic-
ipants originally enrolled in either the DART (Dispatch
Assisted Resuscitation Trial) trial or to a randomized trial
performed in Sweden, overall survival was 11% at 1 year, 11%
at 2 years, and 9% at 5 years. After adjustment for potential
confounders, randomization to dispatcher instruction to
perform chest compression only was associated with a lower
risk of death (HR: 0.91, 95% CI: 0.83 to 0.99, p ¼ 0.02).
This more favorable outcome was driven by the initial short-
term effects, providing evidence that those early differences
may translate into meaningful public health beneﬁts.
Important limitations of this study should be considered: the
rescue breathing instructions suggested a ratio of 2 breaths
for every 15 compressions; it is possible that 2:30 would result
in better outcomes. It is also important to emphasize that
this study involved only dispatcher-assisted lay person CPR.
The growing importance of chest compressions during
CPR highlights the importance of a related research ques-
tion addressed this year: what is the ideal chest compression
rate? To answer this, Idris et al. examined monitor-
deﬁbrillator recordings from 3,098 patients 20 years with
OHCA between 2005 and 2008 treated by emergency
medical services in multiple sites in the United States and
Canada participating in the Resuscitation Outcomes
Consortium (51). One thousand eighty-two (35%) had
spontaneous return of circulation and 265 (9%) survived to
hospital discharge. Statistical analyses revealed that return
of spontaneous circulation peaked at chest compression
rates of approximately 125 per minute during the ﬁrst 5 min
of CPR. Those with chest compression rates <75 per
minute had a particularly low rate of return of spontaneous
circulation. However, no relationship between chest com-
pression rate and survival to hospital discharge could be
detected. An important limitation of this study includes the
fact that only w20% of all treated cases had electronic ﬁles
available for analysis and important differences that may
have inﬂuenced outcomes existed between those with and
without electronic ﬁles.
Transitioning from OHCA to inpatient cardiac arrests,
2 major publications stemming from the GWTG (Get
with the Guidelines)-Resuscitation registry revealed en-
couraging results. Among 374 hospitals participating in the
registry, 84,625 hospitalized patients had a cardiac arrest
between the years 2000 and 2009 (52). The majority (79%)
had an initial rhythm of asystole or pulseless electrical
activity, while the remainder had VF or pulseless VT. Risk-
adjusted rates of survival to discharge increased from 14%
in 2000 to 22% in 2009, yielding an adjusted rate ratio of
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addition, rates of clinically signiﬁcant neurologic disability
among survivors decreased over time, with a risk-adjusted
rate of 33% in 2000 to 28% in 2009 (p ¼ 0.02 for trend
in the reduction in the adjusted rate ratio). Therefore, while
the prognosis of patients with inpatient cardiac arrest
remains poor, survival is improvingdfortunately, this does
not appear to be at the cost of survival in the setting of
worse neurologic outcomes. Chan et al. extended these
ﬁndings to longer-term follow-up by linking data from the
GWTG-Resuscitation registry with Medicare ﬁles in 6,972
adults 65 years of age or older who were discharged from the
hospital after an inpatient cardiac arrest between the years
2000 and 2008 (53). One year after discharge, 59% of these
patients were alive, and 34% had not been readmitted to
the hospital. The risk of death was higher among older
patients, men, blacks, and those with more severe neurologic
disability. The 3-year survival among these patients was
similar to a cohort of patients hospitalized with HF over the
same time period. These data suggest that, while the prog-
nosis is not generally favorable, survivors of inpatient cardiac
arrest have similar survival to patients with other serious
medical conditions.Cardiac Rhythm Devices
Implantable cardioverter-deﬁbrillators. The MADIT-
RIT (Multicenter Automatic Deﬁbrillator Implantation
Trial–Reduce Inappropriate Therapy) trial asked a very
important clinical question in ICD management: Does
a higher VF detection rate or a longer duration of moni-
toring delay before the initiation of therapy decrease the
number of patients receiving inappropriate antitachycardia
pacing (ATP) or shocks without increasing morbidity
or mortality (54)? In this multicenter, prospective study,
primary prevention ICD patients were randomized to 3
groups. The high rate group (n ¼ 500) had a single detec-
tion zone with a higher VF detection rate (200 beats/min
with a 1.0-s monitoring delay). The delayed-therapy group
(n ¼ 486) had 2 detection zones with longer monitoring
delays (zone 1: 170 to 199 beats/min with a 60-s delay; zone
2: 200 to 250 beats/min with a 12-s delay and rhythm
detection on; zone 3: >250 beats/min with a 2.5-s delay).
The conventional group (n ¼ 514) had 2 detection zones
with shorter delays (zone 1: 170 to 199 beats/min with a 2-s
delay and atrial discriminators turned on; zone 2: 200
beats/min with a 1.0-s delay). When compared to the
conventional group, the high rate and the delayed-therapy
group had signiﬁcantly fewer patients with a ﬁrst occur-
rence of appropriate or inappropriate therapy (79% and 76%
reductions for the high rate group and delayed-therapy
groups, respectively) and with any occurrence of therapy as
well as fewer total occurrences of appropriate and inappro-
priate therapy (mostly due to reductions in ATP). The
conventional group had a signiﬁcantly higher cumulative
mortality during the 2.5 years of follow-up than did thehigh-rate (55% reduction) and delayed therapy groups (45%
reduction). The frequency of syncope was similar among the
3 groups. While the exact reasons for this remain unclear,
this observation suggests that primary prevention ICD
recipients may tolerate longer durations of ventricular
tachyarrhythmias much better than conventionally believed.
The most important point of this study is that, among
patients with primary prevention ICDs, programming
a relatively high detection rate and/or waiting for self-
termination of ventricular tachyarrhythmias is safe and not
associated with more adverse events. An expected conse-
quence of such programming approach was a reduction in
therapy, which was associated with lower mortality when
compared to the conventional therapy group. It remains
unclear why those with more inappropriate ATP experi-
enced a higher rate of death. Since the study was initiated,
more sophisticated discrimination algorithms using a
combination of atrial and ventricular timing and mor-
phology matching have been developed. With imple-
mentation and proper programming of such algorithms,
the incidence of inappropriate therapy and its adverse
consequences will likely be further decreased (especially for
AF or atrial tachyarrhythmias). These discrimination algo-
rithms, in combination with a shorter monitoring delay,
may provide a more reassuring programming option for
patients with ICDs implanted for secondary prevention.
In order to further identify patients with a low LVEF
who would beneﬁt most from ICD implantation, the
MADIT-II (Multicenter Automatic Deﬁbrillator Implan-
tation Trial-II) trial investigators previously used subset
regression analysis to create a simple score for risk strati-
ﬁcation based on 5 high-risk clinical factors: NYHA
functional class >II, age >70 years, blood urea nitrogen
>26 mg/dl, QRS duration >0.12 s, and AF (55). ICD
mortality beneﬁt was observed only among intermediate
risk patients (1 or 2 risk factors). Patients with low risk
(score ¼ 0) and very high-risk (score 3) received no
mortality beneﬁt from ICD implantation. The former had
very low mortality (8% over 2 years) even without an ICD
despite a low LVEF, whereas high-risk patients (score 3)
had such high mortality (50% over 2 years) from multiple
comorbidities that ICD implantation failed to reduce overall
mortality. This scoring system, based on 1.5 years of follow-
up data, has served as a very practical tool in reﬁning our
selection of patients for ICD therapy. More recently,
re-examination of the data after an average of 8 years of
follow-up showed persistent signiﬁcant survival beneﬁt
with an ICD among intermediate risk patients (with
a 34% mortality risk reduction; HR: 0.66, p < 0.001), and
no signiﬁcant ICD beneﬁt among high risk patients (19%
vs. 17% 8-year survival rates for ICD and control groups;
HR: 0.84, p < 0.25) (56). In contrast to the earlier report,
ICD implantation was associated with a pronounced 48%
reduction in 8-year mortality (p < 0.001) for the low-risk
patients. This remarkable change was attributed to impor-
tant time-dependent changes in the clinical characteristics
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can be argued that instead of implanting ICDs in the low-
risk patients, they can be followed closely for changes in
their clinical characteristics, at which point an ICD can be
implanted for its mortality beneﬁts.
Based on Medicare data from more than 45,000 primary
prevention ICD patients, a model of predicting ICD patient
survival was developed (57). Seven clinical predictors of
mortality were identiﬁed: chronic kidney disease (HR: 2.33,
95% CI: 2.20 to 2.47), 75 years of age or older (HR: 1.70,
95% CI: 1.62 to 1.79), chronic obstructive pulmonary
disease (HR: 1.70, 95% CI: 1.61 to 1.80), diabetes (HR:
1.43, 95% CI: 1.36 to 1.50), NYHA functional class III
(HR: 1.35, 95% CI: 1.29 to 1.42), AF (HR: 1.26, 95% CI:
1.19 to 1.33), and LVEF 20% (HR: 1.26, 95% CI: 1.20 to
1.33), in descending order of their HRs. A nomogram
relating these 7 predictors and survival probability for years 1
to 4 after ICD implantation was created. The predicted
survival probability provides an important piece of infor-
mation in deciding if a patient with a given set of clinical
conditions will beneﬁt from ICD implantation for primary
prevention. But unlike the MADIT-2 post-hoc analysis
(55), how one translates this into contraindications for
therapy is not clear.
The SAFE-ICD (Safety of Two Strategies of ICD
Management at Implantation Study) was a multicenter,
prospective study to determine if deﬁbrillation testing
(DFT) was necessary as part of initial ICD and cardiac
resynchronization therapy deﬁbrillator (CRT-D) implanta-
tion (58). The primary endpoint was a composite of severe
complications at ICD implant and sudden cardiac death or
resuscitation. During the 2 years of follow-up, there were
no statistically signiﬁcant differences between endpoints
reached by the DFT group (1.72% among 831 patients) and
the non-DFT group (1.02% among 1,284 patients). Despite
some differences in patient characteristics (the DFT group
had a statistically lower rate of NYHA functional class III or
class IV HF, AF, renal insufﬁciency, hypertension, higher
LVEF, and less use of beta-blockers, statins, diuretics, and
digoxin) in this nonrandomized, observational study, the
result argued strongly for omission, at least selectively, of
DFT at time of initial implantation for primary or secondary
prevention.
In December 2011, the Food and Drug Administration
placed the St. Jude Medical (Sylmar, California) Riata and
Riata ST (Riata/ST) family of high-voltage leads on a class I
recall because of cable externalization with or without elec-
trical malfunctions. In the past year, 3 large, multicenter,
independent, observational survival analyses on these leads
were published. The Veterans Affairs National Cardiac
Surveillance Program compared freedom from all-cause
electrical failures among 1,403 Riata/ST (877 Riata and
526 Riata ST), 6,091 Medtronic (Minneapolis, Minnesota)
Quattro, 5,073 Medtronic Fidelis, and 2,401 Boston
Scientiﬁc (St. Paul, Minnesota) Endotak leads (59). The
5-year failure-free probability of Riata/ST (97.5%) wassigniﬁcantly lower than that of Quattro (99.3%) and
Endotak (99.4%) leads but signiﬁcantly higher than that of
another FDA recall lead, Fidelis (89.6%). The analysis was
limited to electrical failures only; no ﬂuoroscopic data on
cable externalization were included. It is noteworthy that the
smaller diameter (7-F) Riata ST had a higher failure rate
(5-year failure-free rate of 95.5% and failure rate of 0.81%
per device-year) than the larger (8-F) Riata leads (5-year
survival of 98.4% and failure rate of 0.61% per device-
year). In another multicenter study involving 774 Riata
and 307 Riata ST and 1,668 Quattro leads, Abdelhadi et al.
reported that Riata leads had signiﬁcantly lower electrical
failure rates compared to Quattro leads (60). In contrast to
the Veterans Affairs report, Riata ST lead survival (0.40%
per device-year) was similar to Quattro leads. Using a survey
questionnaire, the Canadian Heart Rhythm Society Device
Committee also reported lower electrical failures in Riata
ST lead (3.3% out of 1,512 leads) than in Riata leads (5.2%
of 2,846 leads) (61). In the report by Abdelhadi et al., the
average follow-up times for Riata and Riata ST leads were
4.15 and 3.26 years, respectively, as compared to 5.6 and
4.0 years in the VA study. At year 5, only 314 Riata and
35 Riata ST leads were at risk, whereas in the VA study
554 Riata and 149 Riata ST remained at risk. Because in
the Canadian study the data were collected using survey
methodology and the duration of follow-up for the Riata
ST leads was not speciﬁed, it is difﬁcult to determine if the
rate of failure for Riata was signiﬁcantly better than that of
Riata ST over time. As Riata failure has been known to
increase signiﬁcantly after 4 years, an inadequate duration of
follow-up might explain the discrepancy in Riata/ST elec-
trical failure rates in these studies.
Leads with cable externalization can be electrically intact,
and the exact frequency and progression to electrical
failure has remained largely unknown. In a report from the
Netherlands Heart Rhythm Association Device Advisory
Committee, 1,029 patients with the recalled Riata (n ¼ 484)
and Riata ST leads (n ¼ 545) underwent ﬂuoroscopic and
electrical evaluation. The incidence of externalization was
14.3% (62). The rate appeared to increase with lead age
and was higher in 8–F Riata compared with 7-F Riata ST
leads (21.4% vs. 8.0%). Importantly, the median age was
older for the Riata leads than the Riata ST leads (6.0 years
vs. 4.3 years). Among the 147 leads with externalization,
10.9% had electrical failures versus 3.5% in nonexternalized
leads. Similar ﬁndings were reported by a small study from
Denmark (63). The overall prevalence of externalization was
11%, with the Riata leads at 21% and the Riata ST leads
at 6%. The degree of externalization increased with lead
age. No association was observed between externalization
and electrical function. Not long after the announcement of
the Riata lead recall, the FDA recommended that all Riata
ST leads should undergo ﬂuoroscopic examination for
evidence of cable externalization. However, the recommen-
dation did not include what action to take if externalization
was found in electrically intact leads.
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reports on cardiac resynchronization therapy (CRT) from
post-hoc analysis of the MADIT-CRT (Multicenter
Automatic Deﬁbrillator Implantation Trial With Cardiac
Resynchronization Therapy) data. Compared with ICD
implantation alone, CRT-D was associated with greater
improvement in quality of life, even among relatively
asymptomatic patients (NYHA functional class I or II)
(64). But the improvement was limited to patients with
left bundle branch block (LBBB). Another report evalu-
ated the relationship between CRT-D treatment and
ventricular tachyarrhythmia events (65). Although CRT-D
signiﬁcantly reduced the risk of a ﬁrst ventricular tachyar-
rhythmia event by 29%, primarily in patients with LBBB,
it failed to change the risk of subsequent ventricular
tachyarrhythmia events. In fact, the risks of recurrent ven-
tricular tachyarrhythmia events and subsequent HF or
death were signiﬁcantly increased among non-LBBB
patients. The MADIT-CRT data were further analyzed
to compare the efﬁcacy of metoprolol versus carvedilol (66).
The latter was associated with a 30% reduction in hospi-
talization for HF or death when compared with metoprolol.
This was primarily driven by a synergistic effect of carve-
dilol and CRT-D treatment in patients with LBBB
(a 49% reduction in HF or death when compared with
metoprolol). A pronounced dosage dependent relationship
with outcomes was found in carvedilol, but not in meto-
prolol treated patients. These results strongly suggest that
carvedilol is the beta-blocker of choice in CRT-D patients
with mild HF and LBBB. Analysis of clinical outcomes
(reductions in left ventricular end-diastolic volume, HF,
and death) demonstrated that the clinical beneﬁt of CRT
was maintained regardless of baseline LVEF, including
a subgroup of MADIT-CRT patients with LVEF >30%
(67). It is noteworthy that the latter had a higher frequency
of right bundle branch block and intraventricular conduc-
tion delay (IVCD) and shorter QRS durations, character-
istics that have been shown to be associated with a less
favorable response to CRT therapy in the MADIT-CRT
trial. Super-responders to CRT-D (deﬁned by the top
quartile of LVEF change or LVEF change 14.5%) were
associated with female sex, no prior myocardial infarction,
QRS 150 ms, LBBB, body mass index <30 kg/m2, and
smaller left atrial volume (68). Super-responders had
a reduced risk of subsequent cardiac events, with a cumula-
tive probability of HF or all-cause deaths at 2 years of 4%
as compared to 11% in “responders” (LVEF improvement
of 7.9% to 14.4%) and 26% in hypo-responders (LVEF
changed <7.9%). Analysis of a subgroup of MADIT-CRT
trial patients with nonischemic cardiomyopathy revealed
that statin use was associated with a signiﬁcant reduction
in the risk of life-threatening ventricular tachyarrhyth-
mias (69). Fast VT/VF (>180 beats/min) or death (the
primary endpoint) was reduced by 77%, and appropriate
deﬁbrillation shocks (the secondary endpoint) was reduced
by 46%.The LESSER-EARTH (Evaluation of Resynchroniza-
tion Therapy for Heart Failure) trial was a proof-of-concept,
randomized, double-blind, 12-center study that was
designed to investigate if CRT beneﬁted patients with severe
left ventricular dysfunction and a QRS duration <120 ms
(70). Eighty-ﬁve eligible patients who underwent CRT-D
implantation were randomized to receive either biven-
tricular pacing or no pacing. The mean qualifying LVEF
was 25.2  6.2% in patients randomized to biventricular
pacing and 24.7  4.5% in patients without pacing.
Mean baseline QRS durations were 105.0  9.9 ms and
105.3  10.3 ms for the pacing and nonpacing groups,
respectively. The trial was terminated after 12 months
because of futility and safety concerns. There were no
signiﬁcantly differences in exercise duration, left ventricular
end-systolic volumes, and ejection fractions between the 2
groups. Alarmingly, biventricular pacing signiﬁcantly
reduced the 6-min walk distance, increased QRS duration,
and was associated with a nonsigniﬁcant trend toward an
increase in HF–related hospitalizations. This study added to
a growing body of evidence that CRT should not be
considered in patients with a narrow QRS (<120 ms), even
in the presence of HF with LVEF 35%.
The importance of QRS morphology and duration on
CRT was further conﬁrmed by a post-hoc analysis of the
REVERSE (Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction) trial (71). Among
610 patients with mild HF (NYHA functional class I and II
and LVEF 40%), patients with LBBB (n ¼ 369) experi-
enced a signiﬁcant reduction in LVESVI, whereas non-
LBBB patients did not. Baseline QRS duration was also
a strong predictor of change in LVESVI, with monotonic
increases as QRS duration prolonged. Similarly, the clinical
composite score improved with CRT for LBBB but not
for non-LBBB patients. The association between clinical
composite score and QRS duration was highly signiﬁcant,
with improved responses associated with longer QRS
durations. Importantly, such beneﬁt was due primarily to
the LBBB patients. The change in QRS duration with
CRT pacing was not an independent predictor of any out-
comes after correction for baseline variables.
Pacemakers. The potential beneﬁt of biventricular pacing
in patients who require a high percentage of pacing was
examined in the prospective, randomized and multicenter
BLOCK HF (Biventricular versus Right Ventricular Pacing
in Heart Failure Patients with Atrioventricular Block) trial
(72). CRT with pacing only (CRT-P) or CRT with ICD
capability (CRT-D) devices were implanted in 691 patients
with AV block; NYHA functional class I, II, or III HF; and
LVEF of 50%. They were randomized to right ventricular
pacing or biventricular pacing. The primary outcome was
time to death from any cause, an urgent care visit for HF
that required IV therapy, or a 15% increase in left
ventricular end-systolic volume index. During a 37-month
follow-up period, the primary outcomes occurred in
a signiﬁcantly lower percentage of patients with biventricular
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(56%). The investigators concluded that biventricular pacing
was superior to right ventricular patients with AV block and
left ventricular systolic dysfunction with NYHA functional
class I, II, or III HF. The pre-trial HF burden of the studied
patients, which could inﬂuence the endpoints in the trial,
was not speciﬁed. Overall, this study added more supportive
evidence for consideration of biventricular pacing over
conventional RV pacing when pacing percentage is expected
to be high in patients with an abnormally low LVEF.
Implantation guidelines. The American College of
Cardiology Foundation/American Heart Association/Heart
Rhythm Society focused update of the 2008 guidelines for
device-based therapy of cardiac rhythm abnormalities was
published in 2012 (73). Signiﬁcant changes were focused on
CRT and device remote monitoring. For CRT, the most
signiﬁcant changes were: 1) limitation of the Class I indi-
cation to patients with QRS duration 150 ms; 2) limita-
tion of the Class I indication to patients with LBBB; 3)
expansion of the Class I indication to NYHA functional
class II (and with LBBB with QRS duration 150 ms); and
4) the addition of a Class IIb recommendation for patients
who have LVEF 30%, ischemic etiology of HF, sinus
rhythm, LBBB with a QRS duration 150 ms, and NYHA
functional class I symptoms. Contemporary remote moni-
toring is now recommended as an alternative to in-person
ofﬁce visits for pacemaker, ICD, and CRT devices.Translational Electrophysiology
Atrial ﬁbrillation. Several studies have focused on the role
of altered calcium (Caþþ) metabolism in the geneses of AF.
Shan et al. generated 3 knock in mice models by introducing
ryanodine receptor 2 (RYR2) mutations that caused cate-
cholaminergic polymorphic ventricular tachycardia (CPVT)
in humans (74). They used a model of atrial burst pacing
and showed that induction of AF was far more frequent
(36% to 70%) in the mutant mice but was not observed in
the wild-type mice. Atrial myocytes from mutant mice
showed a signiﬁcant diastolic Caþþ leak. They found that
calstabin2 (FKBP 12.6), a protein known to stabilize the
closed state of RYR, was necessary for stabilizing the Ca
þþ
leak in the model.
While altered Caþþ metabolism has been demonstrated
in humans with chronic AF, it is not clear whether the
abnormality is primary or secondary to structural abnor-
malities (e.g., atrial ﬁbrosis). These studies in mice with
structurally normal hearts suggest a primary role for Caþþ
leak in the geneses of AF. This is especially important
because it is difﬁcult to induce AF in the very small mice
atria.
Voigt et al. (75) studied protein levels, membrane
currents, internal Caþþ, and Caþþ sarcoplasmic reticulum
(SR) content from right atrial tissue samples from 76
patients in sinus rhythm and 72 patients with chronic AF.
They found that the diastolic Caþþ leak was 50% higher insamples from those with chronic AF compared with those
in sinus rhythm. They found that Caþþ/calmodulin-
dependent protein kinase (CaMKII) expression was
increased in those with chronic AF. They also found up-
regulation of the Naþ/Caþþ exchanger (NCX). In their
studies, they found that enhanced SR Caþþ leak through
CaMKII-hyperphosphorylated RYR2 together with en-
hanced NCX causes delayed after-depolarizations in samples
from patients with chronic AF.
The clinical importance of these studies from human
tissues adds to the evidence of the importance of subcellular
Caþþ handling in the geneses of AF. The observations point
to the importance of delayed afterdepolarizations acting as
triggers for development of AF. The role of Caþþ channel
blockers for treatment of patients with chronic persistent
AF is, however, still disputed (76,77).
Genetic arrhythmia syndromes. A series of important new
discoveries related to the inherited arrhythmic syndromes
were reported. At present, pathogenic mutations in 13 genes
have been implicated as causes of the congenital long QT
syndrome (cLQTS). Previous genetic studies on drug-
induced LQTS (diLQTS) were conﬁned to the use
of <5 of the most commonly identiﬁed mutant genes and
identiﬁed possible causative variants in 10% to 20% of
subjects (78). Recently, Ramirez et al. addressed this issue
for patients who presented with drug-induced polymorphic
VT using targeted capture coupled with next generation
sequencing of genes associated with arrhythmic disorders
(79). They found that 11 of 31 (36%) carried a novel mis-
sense mutation in genes with either known arrhythmic
syndrome or with the cLQTS. In the 26 Caucasian subjects,
23% carried a highly conserved variant predicted to be
deleterious compared with only 2 to 4% found in public
databases. The authors concluded that rare variations in
genes were common in diLQTS. This work is especially
important because drugs associated with polymorphic VT
are the most common cause of drug withdrawal or relabel-
ing. Methods to uncover potential patients at risk for
development of diLQTS would be an important step
forward in promulgating personalized medical care.
The hERG gene encodes the pore-forming delayed Kþ
rectiﬁer current known as IKr. Abnormalities in this
current are a known cause of the cLQTS. More impor-
tantly, a variety of drugs (antiarrhythmic agents, antibi-
otics, and antipsychotic drugs) have been implicated as
important causes of diLQTS by blocking the IKr channel.
Potet et al. described their studies using a small molecule
to inhibit drug-induced IKr block in Langendorff-
perfused rabbit hearts (80). They used a high-throughput
assay to screen a library of compounds that would block
the effects of dofetilide (a known pure IKr blocker).
Ventricular arrhythmias were induced with a ventricular
stimulation protocol using a rabbit model because the
rabbit heart is rich in IKr. They found that 1 particular
compound, VUO405601, had little independent effect
but could block the inhibition of IKr by dofetilide and
Marcus et al. JACC Vol. 62, No. 25, 2013
Year in Review of EP December 24, 2013:2433–47
2444signiﬁcantly decrease the generation of ventricular
arrhythmias associated with dofetilide.
This important study shows that drugs may be developed
to block the potentially life-threatening arrhythmias from
diLQTS. These ﬁndings have important implications both
for the immediate therapy of diLQTS as well as a potential
for salvaging valuable drugs that currently are blocked from
the market because of prolonged QT actions. This study
supports the prior basic studies of Antzelevitch et al., which
demonstrate that ranolazine, a late Naþ channel blocker,
may be effective in the treatment of laboratory induced drug-
related torsades de pointes (81).
Arrhythmogenic right ventricular cardiomyopathy
(ARVC) is a disease entity characterized by ﬁbro-fatty
inﬁltration of predominantly the right ventricle and is
associated with a high incidence of ventricular arrhythmias.
The disease is associated with genetic mutations in the
desmosomal proteins, particularly plakophilin 2. Prior
studies have shown that mutant plakophilin 2 (PKP2)
proteins result in failure to anchor plakoglobin to the
sarcolemmal membrane, resulting in nuclear translocation
and down regulation of beta-catenin activity (82). However,
no exaggerated lipogenesis or apoptosis were found. More
recently Kim et al. used cellular reprogramming of somatic
cells to induced pluripotent stem cells from 2 patients with
ARVC associated with PKP2 mutations (83). They found
that the mutant PKP2 cells demonstrated abnormal plako-
globin translation and decreased b-catenin activity, but this
was insufﬁcient to replicate the characteristic features of
ARVC. There are major differences between embryonic and
adult cardiomyocyte metabolism. The embryonic cells use
mostly glycolysis for energy production as opposed to adult
myocytes, which use fatty acid oxidation but retain capacity
for a switch to glucose utilization when fatty acids are not
available. By exposing cells to a variety of promoters, they
found that activation of peroxisome proliferator-activated
receptor (PPAR)-a (the major regulator of fatty acid in
adult cardiomyocytes) as well as PPAR-g resulted in cardiac
apoptosis and lipogenesis in heart embryoid bodies. After
coactivation of PPAR-a and PPAR-g, there was overall
depressed energy metabolism with an 86% reduction in fatty
acid and 74% reduction in glycolysis, resulting in a fuel shift
to dominate glucose utilization as observed in failing hearts
(84). In summary, this very comprehensive study showed
that use of induced pluripotent stem cells from ARVC
patients with PKP2 mutations resulted in activation of both
PPAR-a and PPAR-g, with a notable shift representing
a phenocopy of ARVC. This is a potentially important
model to assess effects of various agents that may counter the
abnormal metabolic effects.
CPVT is characterized by exercise or emotionally
provoked bidirectional or polymorphic VT in patients
without structural cardiac disease. Mutations in RYR2 or
Calsequestrin account for approximately 50% of CPVT
cases. In an exciting new study, Nyegaard et al. described 1
family and 1 patient in whom a CPVT phenocopy wasfound (85). Applying a genome-wide linkage analyses
to the family, the disease was localized to chromosome
14. Further sequencing encoded a heterozygous missense
mutation in calmodulin 1 (CALM1) with excellent disease
segregation in the family. A different missense mutation in
CALM1 was identiﬁed in the patient. Prior studies have
established that calmodulin binds directly to RYR2 and that
this interaction decreases the open probability of RYR2 (and
hence absent diastolic-release of Caþþ). On the basis of this
report, the CALM1 mutations that are characterized as
having a “loss of function” with regard to RYR2 interaction
should lead to leaky channels and thus explain the similar
CPVT phenocopy. This important study adds to the
growing number of mutations now found to be associated
with the CPVT phenocopy and include mutations in
KCNJ2, (associated with Andersen-Tawil syndrome) as well
as ANK2 (cLQTS type 4).
Cutler et al. from the late Dr. David Rosenbaum’s lab
reported on the gene transfer of SR Caþþ ATPase2a
(SERCA2a) into adult guinea pigs with HF (86). It is
known that HF is associated with both decreased SER-
CA2a function as well as enhanced susceptibility to elec-
trical alternans and ventricular arrhythmias (87–89). Recent
clinical trials have shown that increased expression of
SERCA2a improved cardiac function in HF (90). The
authors used a guinea pig model of HF by means of
banding the aorta. Gene delivery of SERCA2a DNA was
accomplished using an adeno-associated viral vector. The
authors found that isolated myocytes demonstrated slower
SR calcium uptake and increased diastolic Caþþ concen-
trations compared with controls. Heart failure was associ-
ated with increased susceptibility to electrical alternans
and ventricular arrhythmias. In vivo gene transfer improved
left ventricular contractile force and suppressed both
alternans and inducible ventricular arrhythmias. They also
found that Caþþ/calmodulin-dependent protein kinase II-
mediated RYR2 phosphorylation was increased in HF but
was reduced in those undergoing gene transfer. The latter
action would be expected to decrease diastolic Caþþ leak
and propensity for arrhythmias. This important work
lends further insight into the association of HF, cardiac
arrhythmias and abnormal subcellular Caþþ handling. Up-
regulation of SERCA2a function by gene transfer remains
an exciting possibility for clinicians.
Further insights into the complexity of subcellular Caþþ
handling were elaborated in a manuscript by DeGrande
et al. (91). Ankyrin-B is known to modulate the function of
multiple proteins involved in depolarization and repolari-
zation, including the Naþ/Kþ ATPase and Naþ/Caþþ
exchangers. Patients with ankyrin-B deﬁciency mutations
may present with a clinical picture of CPVT. De Grande
et al. (91) showed another important effect of ankyrin-B
deﬁciency in mice. They found that such deﬁciencies
resulted in hyperphosphorylation of the RYR2 receptors due
to altered CaMKII activity. They showed that use of a
potent CaMKII inhibitor prevented ankyrin-B cellular
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2445afterdepolarizations as well as fatal cardiac arrhythmias.
These important studies reveal yet another important facet
of ankyrin-B function as it relates to Caþþ handling and the
geneses of ventricular arrhythmias.
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